Sanofi Profit Little Changed as Drugmaker Pursues Medivation

  • CEO Brandicourt `concerned' patients aren't getting Praluent
  • Outlook confirmed for `broadly stable' profit in 2016

Sanofi’s first-quarter profit showed little change as a new cholesterol medicine faced hurdles in the U.S., underscoring the French drugmaker’s drive to kindle growth with a takeover of Medivation Inc.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.